Class III .BETA.-Tubulin Expression in Tumor Cells is Correlated with Resistance to Docetaxel in Patients with Completely Resected Non-Small-Cell Lung Cancer

Hayashi, Yoshiki; Kuriyama, Hideyuki; Umezu, Hajime; Tanaka, Junta; Yoshimasu, Tatsuya; Furukawa, Tomoko; Tanaka, Hiroshi; Kagamu, Hiroshi; Gejyo, Fumitake; Yoshizawa, Hirohisa

doi:10.2169/internalmedicine.48.1659

Cited by 34 publications

(27 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, low β-tubulin III expression was associated with improved outcome after taxane-based neoadjuvant chemotherapy and surgical resection in a cohort of Korean patients [53]. Several other studies in agreement with these results have been reported, suggesting a potential use of β-tubulin III expression as a tool to select patients [10, 54,55].…”

Section: Taxanessupporting

confidence: 58%

Impact of biomarkers on non-small cell lung cancer treatment

Toschi

Cappuzzo

2010

Targ Oncol

View full text Add to dashboard Cite

Chemotherapy represents the mainstay of non-small cell lung cancer (NSCLC) treatment, but response is usually observed in only one out of three patients. Massive efforts have been carried out to identify biomarkers that might help clinicians to choose appropriate drugs, by identifying potentially sensitive subjects and spare toxicities in patients who are unlikely to benefit from treatment. Low excision repair cross-complementation group 1 (ERCC1) and ribonucleotide reductase M1 (RRM1) levels have been associated with increased sensitivity to cisplatin and gemcitabine, respectively, while reduced class III beta-tubulin expression has been associated with taxane activity. Initial prospective studies showed the feasibility of a customized approach based on biomarker assessment, and phase III trials will hopefully provide further validation of this approach. The impact of biomarkers for patient selection has now been well established for tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR), with EGFR mutations emerging as the most reliable predictor for improved outcome. Relevant clinical issues are represented by the identification of patients who can be reasonably excluded from treatment and by the development of therapeutic approaches able to overcome acquired resistance to anti-EGFR strategies.

show abstract

Section: Taxanessupporting

confidence: 58%

Impact of biomarkers on non-small cell lung cancer treatment

Toschi

Cappuzzo

2010

Targ Oncol

View full text Add to dashboard Cite

show abstract

“…Briefly, fresh tumour specimens were cut into small pieces of approximately 10 mg and then placed on prepared collagen surfaces in 24-well microplates. After treatment with docetaxel and cisplatin at the concentration of 100 μ g ml –1 (Hayashi et al , 2009) and 20 μ g ml –1 (Fujita et al , 2009), respectively, 3-(4,5-dimethyl-2-thiazotyl)-2,5-diphenyl-2H-tetrazoliumbromide assay was used to examine cytotoxicity. The inhibition rate was calculated as previously reported (Shen et al , 2012).…”

Section: Methodsmentioning

confidence: 99%

Differential effect of MMSET mRNA levels on survival to first-line FOLFOX and second-line docetaxel in gastric cancer

et al. 2014

View full text Add to dashboard Cite

Background:Breast cancer susceptibility gene 1 (BRCA1) expression differentially affects outcome to platinum- and taxane-based chemotherapy. Mediator of DNA damage checkpoint protein 1 (MDC1), p53-binding protein 1 (53BP1), multiple myeloma SET domain (MMSET) and ubiquitin-conjugating enzyme 9 (UBC9) are involved in DNA repair and could modify the BRCA1 predictive model.Methods:Mediator of DNA damage checkpoint protein 1, 53BP1, MMSET and UBC9 mRNA were assessed in gastric tumours from patients in whom BRCA1 levels had previously been determined.Results:In vitro chemosensitivity assay, MMSET levels were higher in docetaxel-sensitive samples. In a separate cohort, survival was longer in those with low MMSET (12.3 vs 8.8 months; P=0.04) or UBC9 (12.4 vs 8.8 months; P=0.01) in patients receiving only folinic acid, fluorouracil (5-FU) and oxaliplatin (FOLFOX). Conversely, among patients receiving second-line docetaxel, longer survival was associated with high MMSET (19.1 vs 13.9 months; P=0.003). Patients with high MMSET and BRCA1 attained a median survival of 36.6 months, compared with 13.9 months for those with high BRCA1 and low MMSET (P=0.003). In the multivariate analyses, low MMSET (hazard ratio (HR), 0.59; P=0.04) and low UBC9 (HR, 0.52; P=0.01) levels were markers of longer survival to first-line FOLFOX, whereas palliative surgery (HR, 2.47; P=0.005), low BRCA1 (HR, 3.17; P=0.001) and low MMSET (HR, 2.52; P=0.004) levels were markers of shorter survival to second-line docetaxel.Conclusions:Breast cancer susceptibility gene 1, MMSET and UBC9 can be useful for customising chemotherapy in gastric cancer patients.

show abstract

“…Hayashi et al [27] provided evidence that ␤III tubulin expression is predictive of poorer outcomes following taxane-based therapy, but not following gemcitabine therapy, in patients (N = 58) with completely resected NCSLC. As observed in the advanced disease setting, these data suggest that ␤III tubulin expression has predictive value for response to taxanes.…”

Section: Clinical Evidencementioning

confidence: 99%

The role of βIII tubulin in predicting chemoresistance in non-small cell lung cancer

2010

View full text Add to dashboard Cite

Class III .BETA.-Tubulin Expression in Tumor Cells is Correlated with Resistance to Docetaxel in Patients with Completely Resected Non-Small-Cell Lung Cancer

Abstract: Objective To assess the relationship between in vitro chemosensitivity evaluated by the histoculture drug response assay (HDRA)

Cited by 34 publications

References 30 publications

Impact of biomarkers on non-small cell lung cancer treatment

Impact of biomarkers on non-small cell lung cancer treatment

Differential effect of MMSET mRNA levels on survival to first-line FOLFOX and second-line docetaxel in gastric cancer

The role of βIII tubulin in predicting chemoresistance in non-small cell lung cancer

Contact Info

Product

Resources

About